Will the tide turn for the wave of pharma layoffs?
Pharmaceutical Technology
OCTOBER 30, 2024
Pharmaceutical management expert Kenneth Getz shares insights on broader trends in the pharma sector influencing the recent wave of layoffs.
Pharmaceutical Technology
OCTOBER 30, 2024
Pharmaceutical management expert Kenneth Getz shares insights on broader trends in the pharma sector influencing the recent wave of layoffs.
Bio Pharma Dive
OCTOBER 30, 2024
All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 30, 2024
GlaxoSmithKline (GSK) has entered an agreement to acquire Chimagen Biosciences’ CMG1A46 for $300m upfront.
Bio Pharma Dive
OCTOBER 30, 2024
Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed capital.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Rethinking Clinical Trials
OCTOBER 30, 2024
Dr. Thomas Carton and Dr. Anitha John In this Friday’s PCT Grand Rounds, Thomas Carton of the Louisiana Public Health Institute and Anitha John of George Washington University and the Children’s National Hospital will present “Congenital Heart Initiative: Redefining Outcomes and Navigation to Adult Centered Care (CHI-RON) Study.” The Grand Rounds session will be held on Friday, November 1, 2024, at 1:00 pm eastern.
Bio Pharma Dive
OCTOBER 30, 2024
The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision therapies for neurological diseases, one investor told BioPharma Dive.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
OCTOBER 30, 2024
Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to the second quarter amid inventory decreases in the U.S.
Pharmaceutical Technology
OCTOBER 30, 2024
Barman-Aksӧzen shared her experience of guiding treatment research for her own ultra rare disorder, erythropoietic protoporphyria (EPP).
Bio Pharma Dive
OCTOBER 30, 2024
The partners no longer intend to develop Zurzuvae for one of the most common forms of depression, citing the time and cost of running new studies that would satisfy the FDA.
Pharmaceutical Technology
OCTOBER 30, 2024
Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare conditions.
Bio Pharma Dive
OCTOBER 30, 2024
Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business, according to one analyst.
Pharmaceutical Technology
OCTOBER 30, 2024
The Kalihinol analogue is an innovative approach to malaria treatment, targeting the apicoplast to undermine P falciparum’s functions.
Bio Pharma Dive
OCTOBER 30, 2024
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of its competing RSV shot.
Pharmaceutical Technology
OCTOBER 30, 2024
With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Rethinking Clinical Trials
OCTOBER 30, 2024
Speaker Nicholas Bloom, PhD Professor of Economics Stanford University Slides Keywords Remote Work; Hybrid Work; Job Performance; Attrition Key Points Dr. Bloom conducted a randomized controlled trial at the Trip.com headquarters in Shanghai to test the efficacy of a hybrid WFH model. 1,612 employees in the IT and Airfare divisions were randomized to come into the office either five days/week (the control arm) or three days/week, with the option to
Pharmaceutical Technology
OCTOBER 30, 2024
Amidst a share value slump and executive turmoil, Pfizer reported a robust quarter thanks in part to Covid-19 drug sales.
pharmaphorum
OCTOBER 30, 2024
Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for drugs in its class.Simply shifting one vial of the anti-amyloid antibody from the first infusion to the third infusion of the titration phase of dosing – the period used to achieve therapeutic levels in the body – is enough to lower the incidence of a potentially serious side effect known as ARIA-E, accordi
Pharmaceutical Technology
OCTOBER 30, 2024
Novartis has received FDA accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Ph+ CML-CP.
pharmaphorum
OCTOBER 30, 2024
Novartis says FDA approval for frontline use of its leukaemia drug Scemblix will boost the number of eligible patients four-fold, as it hunts blockbuster sales
Pharmaceutical Technology
OCTOBER 30, 2024
Bladder cancer is the ninth most common cancer globally, and the number of diagnosed incident cases is set to increase.
pharmaphorum
OCTOBER 30, 2024
Discover how leveraging AI can help biopharma companies future-proof their operations and strategies. Learn about innovative AI strategies that can drive success in the biopharma industry.
Pharmaceutical Technology
OCTOBER 30, 2024
Lilly’s Alzheimer’s drug Kisunla was approved in the US, Japan, and the UK, among other countries.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
OCTOBER 30, 2024
Following reports of an ex-AstraZeneca executive being detained in China, the company acknowledged that its current president in the country, Leon Wang, "is cooperating with an ongoing investigatio | Following a report of an ex-AstraZeneca executive being detained in China, the company acknowledged that its current president in the country, Leon Wang, "is cooperating with an ongoing investigation.
Pharmaceutical Technology
OCTOBER 30, 2024
Green chemistry has the potential to revolutionise the pharmaceutical industry.
pharmaphorum
OCTOBER 30, 2024
The recent FDA decision on the use of MDMA for PTSD treatment has created uncertainty about the future of psychedelic therapy. Learn more about the implications and potential impact on patients.
Fierce Pharma
OCTOBER 30, 2024
Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
OCTOBER 30, 2024
The UK's first female Chancellor Rachel Reeves pumps billions into NHS in the first Labour budget in 14 years
Fierce Pharma
OCTOBER 30, 2024
Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculat | Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of analyst expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation that skyrocketing demand for the blood sugar modulating treatments has maxed out.
Drug Patent Watch
OCTOBER 30, 2024
The pharmaceutical industry is known for its complex regulatory environment and lengthy product development processes. One often overlooked aspect of this industry is the potential benefits of abandoned and expired patents. These patents can provide opportunities for companies to bring new products to market at a lower cost and with reduced development time.
Fierce Pharma
OCTOBER 30, 2024
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the British drugmaker. For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content